Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.
about
Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replicationDifferences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques; a pilot studyHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.SIVsm Tat, Rev, and Nef1: functional characteristics of r-GV internalization on isotypes, cytokines, and intracellular degradation.Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine designMucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3)Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.Viral exploitation and subversion of the immune system through chemokine mimicry.Challenges and opportunities for development of an AIDS vaccine.The infiltration kinetics of simian immunodeficiency virus-specific T cells drawn to sites of high antigenic stimulation determines local in vivo viral escape.Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individualsTat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.Novel biopanning strategy to identify epitopes associated with vaccine protection.Tat-neutralizing antibodies in vaccinated macaques.The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile.Antigen-specific B cell detection reagents: use and quality controlMonocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogensEffect on HIV-1 gene expression, Tat-Vpr interaction and cell apoptosis by natural variants of HIV-1 Tat exon 1 and Vpr from Northern IndiaT-cell and neuronal apoptosis in HIV infection: implications for therapeutic intervention.A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rheAvoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development.Problems and emerging approaches in HIV/AIDS vaccine development.Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat.
P2860
Q24673389-63E415D8-038C-4637-919E-A8108FE5FD8FQ24684750-A4A1BE3A-DD35-428B-B49D-93893E06248DQ24802232-B9D56A6B-5937-45C4-9ACB-CCEE678C4843Q30381447-781A3416-DF6C-46AB-AF30-85DEC8AECBA4Q33636080-AC7504FD-C88B-4DA5-9F63-F1F393F88592Q33845527-8EB3723D-04A8-4838-B6BB-45B4718AC085Q33855093-D6F6B0D7-A620-4550-A48C-5C16BF74B537Q33908773-E4238F7E-E62A-473E-8E34-4E28BB732797Q33933260-F86E20C0-FF3D-4258-8D59-A2E8E3727A56Q33942996-D6187173-8E1B-40DA-A520-D7329489F94EQ33949260-D1F23638-85A0-4976-B89D-FABA2CFC562EQ33984182-AC33297D-5DAF-4E19-A39D-21E25FA804A8Q34098868-5FD055CC-3B12-47D2-B12C-84E9AB91BDC9Q34104267-8CD9642C-E1BD-4756-B8CF-DB661F4D4F79Q34336210-8BCC2776-10E1-48E6-904E-FEDBA74CF3EFQ34488930-86A43EA8-1E39-48BB-8E21-7C16A27E0033Q34579037-712560A0-BEFB-4DA2-8BE8-15ED9BCCDDDEQ34755910-F1F00D41-A203-475E-9902-1B46957830A9Q34756847-E4DA74E0-1D77-438D-9087-4E15A8117E02Q35017758-DE2A9543-14F1-42D2-BBDF-F64C99446FE3Q35020357-F2739A0F-1A69-4D0F-A498-E2AA13B2204CQ35024266-DF2DDB44-B22F-4186-BCCE-213644A65C99Q35075250-812DA163-6FBA-4A99-915F-45D2C818AE8AQ35613792-2E03A65A-EA22-4AC8-8E6C-54A185E9A838Q35785031-03EB235E-9B4B-4170-8607-1552189E2286Q35888732-D1385558-73B2-47F9-ADE2-342389105EA3Q36758574-0491F6B1-373D-43C5-869E-DBFDB12D5DBAQ36961218-8F6987B3-9758-4D4F-9E90-FE2013F182D8Q37009569-0046A857-6DEA-48F0-8946-0E8895563530Q37220038-6C44EDB3-AD9A-41D8-8A95-AC3DC66064E4Q37348901-5605E4AC-1C69-465F-8465-8BB1A7168BF7Q37730488-1521925B-D651-474B-8B40-AA7A384062F5Q39683362-63F6DB71-F038-4BAA-B7BB-B58DB0FF1BC8Q39699309-54CBD320-D048-4341-8635-02BE69CEE87DQ40273841-029425FE-D423-4BA9-BB55-BA2F35718CADQ40551477-EA980A3A-1294-45B4-93AB-64FC0ACCFD18Q40812571-B8FD0278-6D4A-4EC3-B7E8-C282D343778C
P2860
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.
@ast
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.
@en
type
label
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.
@ast
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.
@en
prefLabel
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.
@ast
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.
@en
P2093
P2860
P356
P1476
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.
@en
P2093
H Le Buanec
T J Ruckwardt
P2860
P304
P356
10.1073/PNAS.97.7.3515
P407
P50
P577
2000-03-01T00:00:00Z